Diagnosing Seronegative Sjogren's Disease Save
Sjögren disease (SjD) is highly prevalent, but diagnosis may be challenged if anti-SSA antibodies or a labial salivary gland biopsy are negative. A recent cohort analysis suggests a novel autoantibody profile has predictive value SSA negative SjD and also in those with a positive labial biopsy.
It is estimated that one-third of SjD patients lack anti-SSA antibodies (SSA−), thereby requiring a positive biopsy and focus score (FS) for diagnosis.
IgG autoantibody binding was assess in 3 cohorts: a) SSA− SjD (n=76), b) sicca-controls without autoimmunity (n=75) and c) autoimmune-feature controls (SjD features but not meeting SjD criteria; n=41).
They found IgG binding to D-aminoacyl-tRNA deacylase (DTD2) more in SSA− SjD compared to sicca-controls (p=0.004) and combined controls (sicca-controls and autoimmune-feature controls combined; p=0.003).
IgG against peptides from retroelement silencing factor-1 and DTD2 were also found more frequently in FS-positive than FS-negative participants (p=0.010; p=0.012).
These findings require further study to delineate their utility in diagnosing SjD, especially those who are seronegative for SSA antibodies.
Join The Discussion
Thanks, Jack. It truly is a study with real-world potential implications. Dr. McCoy plans on checking anti-DTD2 in seropos pts and sicca mimics like hep C, IgG4 dz, and systemic sclerosis. Please remember, everyone, Sjogren's disease is underdiagnosed, even in rheumatology clinics.
Thanks DT. I liked that she was tackling the concept of can you have Sjogrens in the face of SSA, SSB negativity.
I wonder how this biomarkers compared to the tissue specific autoantibodies (TSA) anti-CA6, SP1 and PSP?
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.